Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Organon & Co.
(NY:
OGN
)
14.90
-0.15 (-1.00%)
Streaming Delayed Price
Updated: 12:57 PM EST, Dec 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Organon & Co.
< Previous
1
2
3
4
5
6
7
8
9
Next >
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
May 24, 2024
From
Organon & Co.
Via
Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
May 10, 2024
Via
Benzinga
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
May 07, 2024
From
Organon & Co.
Via
Business Wire
Thursday Is Your Last Chance To Buy Organon Before The Dividend Payout
February 20, 2024
Via
Benzinga
Earnings Scheduled For February 15, 2024
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Organon's Earnings: A Preview
February 14, 2024
Via
Benzinga
Organon Announces Proposed $1.0 Billion Senior Notes Offering
May 07, 2024
From
Organon & Co.
Via
Business Wire
Organon Beats On Q1, Women's Health Leads the Charge
May 02, 2024
Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared.
Via
Benzinga
OGN Stock Earnings: Organon Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
OGN stock results show that Organon beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Organon Reports Results for the First Quarter Ended March 31, 2024
May 02, 2024
From
Organon & Co.
Via
Business Wire
7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024
May 01, 2024
While these sleeper stocks to buy don’t attract the spotlight, the lack of attention makes these ideas even more enticing.
Via
InvestorPlace
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
May 01, 2024
Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology.
Via
InvestorPlace
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
April 08, 2024
From
Organon & Co.
Via
Business Wire
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
April 08, 2024
From
Organon & Co.
Via
Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
March 13, 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
Turn $500 into a Fortune: 3 Top Stock Picks for March’s Million-Dollar Rally
March 07, 2024
Here are three top stock picks for rally have their grip in travel, packaged foods, meats and pharmaceuticals.
Via
InvestorPlace
5 Value Stocks In The Healthcare Sector
March 04, 2024
Via
Benzinga
Drug Maker Organon Stock Scores Relative Strength Upgrade
February 28, 2024
In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.
Via
Investor's Business Daily
Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market
February 26, 2024
Explore growth strategies of overlooked stocks with strong fundamentals in strategic investments and market expansion.
Via
InvestorPlace
New York Attorney General Urges FDA Action On Widely Used Asthma Drug's Concerns Over Pediatric Safety
February 26, 2024
The Attorney General of New York, Letitia James, has called on the FDA to address safety risks associated with the widely used asthma and allergy medicine Singulair (montelukast).
Via
Benzinga
Exposures
Product Safety
Don't Overlook These Low-Risk High-Dividend Yielding Stocks
February 24, 2024
Given the rally in the S&P 500 and the Nasdaq over the last year, it may be wise to consider stocks that should be less volatile during market corrections. Even better is when stocks have dividend...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
February 21, 2024
Jill Biden announces $100 million in federal funding for women's health research, addressing underfunding and lack of awareness. ARPA-H Sprint for Women's Health aims to promote innovative solutions.
Via
Benzinga
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
February 20, 2024
From
Organon & Co.
Via
Business Wire
Why Is Women Health-Focused Organon Stock Trading Higher On Thursday?
February 15, 2024
Organon exceeds Q4 2023 revenue expectations, reaching $1.6 billion. Women's Health thrives with 7% revenue increase, driven by Follistim AQ's 63% growth. Biosimilar revenue surges by 49%.
Via
Benzinga
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 15, 2024
Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings.
Via
Benzinga
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
February 15, 2024
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 15, 2024
From
Organon & Co.
Via
Business Wire
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
February 01, 2024
From
Organon & Co.
Via
Business Wire
Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts?
January 30, 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
5 Value Stocks To Watch In The Healthcare Sector
January 29, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.